Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | PTCL arising as a PTLD: the efficacy of pralatrexate

Owen O'Connor • 19 Jun 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma Pralatrexate

Owen O’Connor, MD, PhD, Columbia University Medical Center, New York, NY, discusses peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder (PTLD) and the efficacy of pralatrexate for the treatment of this condition. To read the specific case report mentioned please use this link: https://www.ncbi.nlm.nih.gov/pubmed/31184235

More from Owen O'Connor

Immunoepigenetic platforms for PTCL treatment
6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
The role of epigenetic modulators in the pathogenesis of lymphomas
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Owen O'Connor • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
iwNHL 2017: The future of lymphoma research and treatment
Owen O'Connor • 8 Sep 2017
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
5:45
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
Owen O'Connor • 3 Oct 2015

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Owen O'Connor • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Owen O'Connor • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Owen O'Connor • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Owen O'Connor • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals